An Open-Label, Phase I Clinical Trial of Super CAR-T With GPC3-Positive Advanced Hepatocellular Carcinoma

Required: GPC3 positive expression (positive)

Must have received: standard systemic therapy

Previous failure of or intolerance to at least two lines of standard systemic therapy

Cannot have received: radiotherapy

Exception: within 2 weeks prior to apheresis

Received radiotherapy...within 2 weeks prior to apheresis

Cannot have received: systemic chemotherapy

Exception: within 2 weeks prior to apheresis

Received...systemic chemotherapy...within 2 weeks prior to apheresis

Cannot have received: immune checkpoint inhibitor

Exception: within 2 weeks prior to apheresis

Received...immune checkpoint inhibitors for the study disease within 2 weeks prior to apheresis

Cannot have received: small-molecule targeted therapy (sorafenib, regorafenib, lenvatinib)

Exception: within 1 week prior to apheresis

received small-molecule targeted therapies such as sorafenib, regorafenib, or lenvatinib within 1 week prior to apheresis

Cannot have received: systemic glucocorticoid therapy

Exception: within 7 days prior to single-plasma donation; inhaled/topical/physiological-dose replacement therapy permitted

Received systemic glucocorticoid therapy within 7 days prior to single-plasma donation; patients currently using or who have recently used inhaled or topical glucocorticoids, as well as those on physiological-dose replacement therapy, are eligible for enrollment